Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees

CRANBURY, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that the Company has proactively taken numerous measures in response to the novel coronavirus (COVID-19)  pandemic to support the rare disease community globally and to ensure the achievement of its 2020 key strategic priorities. In support of its patients, people, and programs, a COVID-19 internal Amicus task force chaired by Chairman & CEO John F. Crowley was established in early March and meets regularly via video conference to assess COVID-19 developments and their impacts on company plans and strategies.

Our Patients. Amicus is committed to providing uninterrupted access to medicines for those who are in need of a treatment. 

• Global supply chains for Galafold are robust and have not been interrupted. Amicus believes the Company will continue to be able to supply this oral precision medicine for any and all people living with Fabry disease who have an amenable variant.
• The Company also has a high degree of confidence that participants enrolled in all clinical studies for AT-GAA for Pompe disease, including the Phase 3 PROPEL study, will continue to receive study drug and that this study will be completed on schedule.
• The Company has taken steps to reinforce and elevate the resources provided to patient community partners, which is also detailed on our corporate website.

Our People. Amicus is aligned with public health strategies designed to prevent the spread of COVID-19 in order to protect our global workforce.

• In addition to instituting social distancing efforts, the Company mandated a work from home policy for all global Amicus offices as of March 12, 2020.
• Amicus is focused on ensuring the health and wellbeing of its global workforce and maintaining the safety of all our employees across the globe. The Amicus Cares internal initiative was launched last week to respond to the needs of employees during this unprecedented global health crisis.
• Company executives and medical personnel are also advising and assisting with local, state and federal authorities in certain instances.

Our Programs. Amicus remains dedicated to delivering high-quality medicines for people living with rare diseases. Toward that end, Amicus has instituted a business continuity plan that it believes ensures the business will continue to perform and deliver on its mission for patients and shareholders. Based on current information, the Company continues to believe it will achieve its 2020 key strategic priorities, including: